M2 macrophages promote PD-L1 expression in triple-negative breast cancer via secreting CXCL1

被引:15
作者
Zhang, Lifen [1 ]
Gu, Shanzhi [2 ]
Wang, Lu [1 ]
Zhao, Lin [1 ]
Li, Tian [1 ,3 ]
Zhao, Xinhan [1 ]
Zhang, Lingxiao [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Oncol, 277 West Yanta Rd, Xian 710061, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Dept Forens Med, Xian 710061, Shaanxi, Peoples R China
[3] Fourth Mil Med Univ, Sch Basic Med, Xian 710032, Peoples R China
关键词
Tumor -associated macrophages; Oncoimmunology; Triple -negative breast cancer; Programmed death-ligand 1; C -X-C motif chemokine ligand 1; TUMOR-ASSOCIATED MACROPHAGES; CELLS;
D O I
10.1016/j.prp.2024.155458
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: M2 macrophages are known to play a significant role in the progression of triple-negative breast cancer (TNBC) by creating an immunosuppressive microenvironment. The aim of this study is to investigate the impact of M2 macrophages on TNBC and their correlation with programmed death-ligand 1 (PD-L1) expression. Methods: We employed a co-culture system to analyze the role of the mutual regulation of M2 macrophages and TNBC cells. Employing a multifaceted approach, including bioinformatics analysis, Western blotting, flow cytometry analysis, ELISA, qRT-PCR, lentivirus infection, mouse models, and IHC, we aimed to elucidate the influence and mechanism of M2 macrophages on PD-L1 expression. Results: The results showed a substantial infiltration of M2 macrophages in TNBC tissue, which demonstrated a positive correlation with PD-L1 expression. CXCL1 exhibited abnormally high expression in M2 macrophages and enhanced the expression of PD-L1 in TNBC cells. Notably, silencing CXCL1 or its receptor CXCR2 inhibited M2 macrophages-induced expression of PD-L1. Mechanistically, CXCL1 derived from M2 macrophages binding to CXCR2 activated the PI3K/AKT/NF- kappa B signaling pathway, resulting in increased PD-L1 expression in TNBC. Conclusion: Broadly speaking, these results provide evidence for the immunosuppressive role of M2 macrophages and CXCL1 in TNBC cells, indicating their potential as therapeutic biomarkers.
引用
收藏
页数:13
相关论文
共 48 条
[1]   PD-L1 expression is regulated by both DNA methylation and NF-κB during EMT signaling in non-small cell lung carcinoma [J].
Asgarova, A. ;
Asgarov, K. ;
Godet, Y. ;
Peixoto, P. ;
Nadaradjane, A. ;
Boyer-Guittaut, M. ;
Galaine, J. ;
Guenat, D. ;
Mougey, V. ;
Perrard, J. ;
Pallandre, J. R. ;
Bouard, A. ;
Balland, J. ;
Tirole, C. ;
Adotevi, O. ;
Hendrick, E. ;
Herfs, M. ;
Cartron, P. F. ;
Borg, C. ;
Hervouet, E. .
ONCOIMMUNOLOGY, 2018, 7 (05)
[2]   Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC [J].
Bao, Xuanwen ;
Shi, Run ;
Zhao, Tianyu ;
Wang, Yanfang ;
Anastasov, Natasa ;
Rosemann, Michael ;
Fang, Weijia .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (01) :189-202
[3]   Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer [J].
Colombo, N. ;
Dubot, C. ;
Lorusso, D. ;
Caceres, M., V ;
Hasegawa, K. ;
Shapira-Frommer, R. ;
Tewari, K. S. ;
Salman, P. ;
Usta, E. Hoyos ;
Yanez, E. ;
Gumus, M. ;
de Mendoza, M. Olivera Hurtado ;
Samouelian, V ;
Castonguay, V ;
Arkhipov, A. ;
Toker, S. ;
Li, K. ;
Keefe, S. M. ;
Monk, B. J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (20) :1856-1867
[4]   Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].
Cortazar, Patricia ;
Zhang, Lijun ;
Untch, Michael ;
Mehta, Keyur ;
Costantino, Joseph P. ;
Wolmark, Norman ;
Bonnefoi, Herve ;
Cameron, David ;
Gianni, Luca ;
Valagussa, Pinuccia ;
Swain, Sandra M. ;
Prowell, Tatiana ;
Loibl, Sibylle ;
Wickerham, D. Lawrence ;
Bogaerts, Jan ;
Baselga, Jose ;
Perou, Charles ;
Blumenthal, Gideon ;
Blohmer, Jens ;
Mamounas, Eleftherios P. ;
Bergh, Jonas ;
Semiglazov, Vladimir ;
Justice, Robert ;
Eidtmann, Holger ;
Paik, Soonmyung ;
Piccart, Martine ;
Sridhara, Rajeshwari ;
Fasching, Peter A. ;
Slaets, Leen ;
Tang, Shenghui ;
Gerber, Bernd ;
Geyer, Charles E., Jr. ;
Pazdur, Richard ;
Ditsch, Nina ;
Rastogi, Priya ;
Eiermann, Wolfgang ;
von Minckwitz, Gunter .
LANCET, 2014, 384 (9938) :164-172
[5]   Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer [J].
Cortes, J. ;
Rugo, H. S. ;
Cescon, D. W. ;
Im, S-A ;
Yusof, M. M. ;
Gallardo, C. ;
Lipatov, O. ;
Barrios, C. H. ;
Perez-Garcia, J. ;
Iwata, H. ;
Masuda, N. ;
Otero, M. Torregroza ;
Gokmen, E. ;
Loi, S. ;
Guo, Z. ;
Zhou, X. ;
Karantza, V ;
Pan, W. ;
Schmid, P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03) :217-226
[6]   PD-L1 as a biomarker of response to immune-checkpoint inhibitors [J].
Doroshow, Deborah Blythe ;
Bhalla, Sheena ;
Beasley, Mary Beth ;
Sholl, Lynette M. ;
Kerr, Keith M. ;
Gnjatic, Sacha ;
Wistuba, Ignacio I. ;
Rimm, David L. ;
Tsao, Ming Sound ;
Hirsch, Fred R. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (06) :345-362
[7]   Combined endocrine and targeted therapy in luminal breast cancer [J].
Goldner, Marcelle ;
Pandolfi, Natasha ;
Maciel, Debora ;
Lima, Julianne ;
Sanches, Solange ;
Ponde, Noam .
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) :1237-1251
[8]   Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer [J].
Huppert, Laura A. ;
Gumusay, Ozge ;
Idossa, Dame ;
Rugo, Hope S. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2023, 73 (05) :480-515
[9]   M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma [J].
Jarosz-Biej, Magdalena ;
Kaminska, Natalia ;
Matuszczak, Sybilla ;
Cichon, Tomasz ;
Pamula-Pilat, Jolanta ;
Czapla, Justyna ;
Smolarczyk, Ryszard ;
Skwarzynska, Daria ;
Kulik, Klaudia ;
Szala, Stanislaw .
PLOS ONE, 2018, 13 (01)
[10]   Total glucosides of paeony inhibit breast cancer growth by inhibiting TAMs infiltration through NF-κB/CCL2 signaling [J].
Jin, Lu ;
Guo, Yingxue ;
Mao, Weiye ;
Wang, Jingwei ;
Jin, Lushuai ;
Liu, Xia ;
Shou, Qiyang ;
Fu, Huiying .
PHYTOMEDICINE, 2022, 104